Azienda Sanitaria Universitaria Friuli Centrale
Verified site
Udine, Italy
Rare diseases
Investigational molecules
Locations
A plain-language summary of the goals, design and what participants do
Patients with Epithelioid pleural mesothelioma are being treated with a combination that includes the chemotherapy drugs cisplatin or carboplatin together with pemetrexed and the antidepressant medication sertraline. The purpose of the study is to compare how long patients stay free from disease worsening, known as progression‑free survival, with results that were seen in earlier research.
During the trial, the chemotherapy agents are given by intravenous infusion, which means the medicine is delivered directly into a vein, while sertraline is taken as a tablet by mouth. Treatment is given in repeated cycles over several months, with regular doctor visits and imaging scans to check the size of the tumor. After the treatment period, patients continue to be monitored for any changes in their health or disease status.
The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.
9 criteria
15 criteria
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
All sites with verified contact details – recruitment status may not be available; ask directly
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
Not yet recruitingJoining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
is a chemotherapy drug that contains platinum. It is given through an IV infusion and works by damaging the DNA of cancer cells, which stops them from growing and dividing. In this trial, cisplatin is one of the chemotherapy options combined with the other drugs to treat advanced pleural mesothelioma.
is another platinum‑based chemotherapy medication. Like cisplatin, it is administered by IV infusion and interferes with the DNA of cancer cells, helping to slow or stop tumor growth. The study uses carboplatin as an alternative to cisplatin in the chemotherapy regimen.
is a chemotherapy agent that blocks the production of DNA and RNA in cancer cells. Given by IV infusion, it helps prevent cancer cells from multiplying. In this trial, pemetrexed is combined with either cisplatin or carboplatin as part of the standard chemotherapy treatment for mesothelioma.
is a medication usually used to treat depression and anxiety. In this study, it is being tested for a possible additional benefit against cancer when taken together with the chemotherapy drugs. Patients take sertraline by mouth in tablet form, and researchers are looking to see if it can improve the time patients live without the disease getting worse.
This drug is given as an intravenous infusion of a clear solution. It is a well‑established chemotherapy medicine that has been approved and studied for many years. It is mainly used to treat solid cancers such as lung, ovarian, testicular cancer and mesothelioma. It works by forming strong links in the DNA of cancer cells, which stops them from dividing, and it belongs to the class of platinum‑based antineoplastic agents.
This medication comes as a film‑coated tablet taken by mouth. It is an approved antidepressant with a large amount of research supporting its safety and effectiveness. It is prescribed for depression, anxiety and related mood disorders, and is being tested as an additional treatment in cancer therapy. It increases the level of serotonin in the brain by blocking its re‑absorption, and it is classified as a selective serotonin reuptake inhibitor (SSRI).
The drug is administered through an intravenous infusion of a sterile solution. It is a widely used and approved chemotherapy agent that has been studied in many cancer trials. It is indicated for cancers such as ovarian, lung and mesothelioma. It damages cancer cell DNA by creating cross‑links, preventing the cells from multiplying, and it is part of the platinum‑based anticancer drug group.
This medicine is delivered as an intravenous infusion of a solution for injection. It is an approved chemotherapy drug with extensive clinical data, especially for certain lung cancers and mesothelioma. It is used to treat malignant pleural mesothelioma and non‑small cell lung cancer. It blocks enzymes needed to make DNA and RNA, which stops cancer cells from growing, and it is classified as an antifolate antimetabolite.
sourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?
Tell us about your condition – we search every trial in Europe and connect you with the right site.